{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016288","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.491781+00:00","generated_at":"2026-06-15T05:27:19.367468+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.82,"calibrated_materiality_score":0.82,"confidence":"high","headline":"ProPhase Labs Q1 revenue down 59% to $19.3M; net income slumps to $0.6M from $12.5M","bullets":["Net revenue $19.3M vs $47.5M YoY; diagnostic services plunged $30.4M as COVID-19 testing dropped from 377K to 120K tests.","Net income $0.6M ($0.03 diluted EPS) vs $12.5M ($0.68) prior year; adjusted EBITDA $3.1M vs $14.6M.","Pharmaloz Manufacturing grew nearly 100% YoY; Nebula Genomics saw over 100% revenue growth.","New $6M stock repurchase program authorized; working capital $42.8M; cash $9.6M.","Acquired exclusive worldwide rights to BE-Smart Esophageal Cancer Test for ~$4.5M ($3.5M cash + $1M stock)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016288","json":"https://secwatch.observer/filing/0001493152-23-016288.json","markdown":"https://secwatch.observer/filing/0001493152-23-016288.md","text":"https://secwatch.observer/filing/0001493152-23-016288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315223016288/0001493152-23-016288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315223016288/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:27:19.367468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e29d12751c11652b592fdc6455b42451aac6621d","claim":"ProPhase Labs, Inc. reported the three months ended March 31, 2023 results: revenue $19.3 million, net income $0.6 million, or $0.03 per diluted share.","evidence_excerpt":"growth. ● Implemented new $6 million stock repurchase program. Financial highlights for the three months ended March 31, 2023, include the following: ● Net revenue of $19.3 million for the three months ended March 31, 2023, as compared to $47.5 million for the three months ended March 31, 2022. ● Net Income of $0.6 million, or $0.03 per diluted share, for","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315223016288/0001493152-23-016288-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$19.3 million"},{"label":"Net income","value":"$0.6 million, or $0.03 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}